The global cutaneous squamous cell carcinoma treatment market is estimated to be valued at US$ 10,309.76 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).
Figure 1. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Region, 2020
The increasing product development and ongoing trials are expected to propel growth of the global cutaneous squamous cell carcinoma treatment market
Major players in the market are focused on drug development for cutaneous squamous cell carcinoma treatment, which is expected to boost the market growth over the forecast period. for instance, in May 2020, Regeneron Pharmaceuticals, Inc., and Sanofi A.S., collaboratively initiated the clinical trial and announced the longer-term results for Libtayo (cemiplimab-rwlc), PD-1 inhibitor from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (cSCC). The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) annual meeting.
Figure 2. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Treatment, 2020
Increasing approvals for cutaneous squamous cell carcinoma treatment in North America is expected to boost the market growth
North America is expected to hold dominant position in the global cutaneous squamous cell carcinoma treatment market, owing to increasing approvals for cutaneous squamous cell carcinoma treatment in this region. For instance, in June 2020, Merck & Co., Inc., a U.S.-based multinational pharmaceutical company received approval for pembrolizumab (KEYTRUDA) from the U.S. Food and Drug Administration (FDA). The drug is approved for the treatment of recurrent or metastatic cutaneous squamous cell carcinoma (cSCC), which is not curable by surgery or radiation.
Global Cutaneous Squamous Cell Carcinoma Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global Cutaneous Squamous Cell Carcinoma Treatment market during the forecast period.
Cutaneous Squamous Cell Carcinoma Treatment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients